All articles
Site OperationsNovember 8, 2026·3 min read

What a Screen Failure Really Costs Your Site

Screen failure rate tells you almost nothing on its own. Here's how to calculate what each failure really costs your site, separate avoidable from unavoidable, and fix the ones you control.

By Trialflow Team

Screen failures are the most under-managed cost center at most research sites. Everyone tracks the screen failure rate because sponsors ask for it. Far fewer sites track what each failure actually costs them — and that gap is where margin quietly disappears.

What a screen failure actually costs

Start with what you spend before you know a patient doesn't qualify:

  • Pre-screening labor. Phone calls, chart review, records requests, eligibility worksheets. For complex protocols this can run several hours per candidate.
  • Consent and visit time. A full screening visit occupies a coordinator, often a sub-investigator, and an exam room for a half day.
  • Procedures. Labs, ECGs, imaging, biopsies. Some are reimbursed on screen failure, many are capped, and some are reimbursed only with documentation most sites submit late or not at all.
  • Recruitment spend. If the referral came from paid advertising, the acquisition cost belongs to the failure, not just to the enrollments.
  • Opportunity cost. The hardest number to see. Every screening slot spent on a candidate who was never going to qualify is a slot unavailable to a candidate who would have.

When sites run this math for the first time, they commonly find that a failed screening visit costs somewhere in the range of a real fraction of a completed enrollment's revenue. On protocols with heavy screening procedures, a high failure rate can make an otherwise acceptable budget unprofitable.

Not all screen failures are equal

The useful distinction isn't failed versus enrolled. It's avoidable versus unavoidable.

Unavoidable failures come from criteria you cannot know in advance: a washout lab, a central read, a biomarker result. Those are a cost of doing business, and the right response is to negotiate screen failure reimbursement that reflects them.

Avoidable failures come from information you could have had earlier — a medication on the exclusion list, a diagnosis date, a prior therapy, a BMI, an A1c from three weeks ago. Every avoidable failure is a pre-screening design problem, not a patient problem.

Start categorizing failures by the specific criterion that triggered them and whether that criterion was knowable before the visit. Two months of this data will tell you exactly where to spend improvement effort.

Practical levers

  1. Reorder your screening sequence. Put the cheapest, most discriminating criteria first. If a protocol excludes on a lab you can pull from existing records, check it before you book the visit, not during it.
  2. Build criterion-specific pre-screen scripts. Generic "are you interested" calls produce generic results. Scripts tied to the top three historical failure reasons for that indication catch far more.
  3. Split screening into two visits when the budget allows. A short, cheap visit for knowable criteria followed by a full visit for the rest shifts cost away from candidates who won't qualify.
  4. Negotiate the screen failure line item with real data. Bring your historical failure rate for similar protocols and the procedure costs involved. Sponsors respond to specifics far better than to general requests for higher caps.
  5. Actually invoice for screen failures. Many sites leave reimbursable failures unbilled because the documentation requirements are tedious. Make it part of visit closeout, not a monthly cleanup task.

The metric worth watching

Track cost per enrolled participant, not screen failure rate. A 70% failure rate on a protocol with cheap screening and generous reimbursement may be perfectly healthy. A 30% rate on a protocol with imaging and no screen failure coverage may be bleeding you. The rate alone tells you nothing about whether you're making money.

Enrolling studies shouldn't be this hard

Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.

Request a Demo